{"denoms":[{"counts":[{"groupId":"BG000","value":"125"}],"units":"Participants"}],"groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"BG000","title":"Idelalisib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.4","value":"62"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"80"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"110"}],"title":"White/Caucasian"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Missing"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"117"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Missing"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"83"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Italy"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Score = 60"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Score = 70"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Score = 80"},{"measurements":[{"groupId":"BG000","value":"44"}],"title":"Score = 90"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"Score = 100"}]}],"description":"Karnofsky performance status classified participants according to their functional impairment. Scores ranged from 0-100, the lower the score, the worse the survival for most serious illnesses.","paramType":"COUNT_OF_PARTICIPANTS","title":"Karnofsky Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72"}],"title":"Folicular lymphoma"},{"measurements":[{"groupId":"BG000","value":"28"}],"title":"Small lymphocytic lymphoma"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"LPL/WM"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Marginal zone lymphoma"}]}],"description":"LPL/WM: Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Disease History","unitOfMeasure":"Participants"}],"populationDescription":"ITT analysis set included enrolled participants who received at least one dose of study drug."}